title: Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer.
abstract: OBJECTIVE
  We evaluated the prevalence of myocardial perfusion defects using myocardial perfusion imaging (MPI) after chemoradiation or radiation therapy (CRT/RT) in lung cancer patients and described their patterns in relation to tumor location.
  
  
  METHODS
  MPI in 44 patients who received RT for lung cancer and 44 control patients were compared. The two groups were comparable in risk factors for coronary artery disease. Data regarding tumor stage and location, interval between CRT/RT and MPI, and mean radiation dose to the heart was collected. The level of radiation delivered to the affected segments of the left ventricle versus the normal segments was compared using the isodose lines on the simulation computed tomography.
  
  
  RESULTS
  Considering all tumor locations, 8 patients (18%) demonstrated MPI defects after CRT/RT versus 9 (20%) in the controls. However, 7 of 18 patients (39%) with centrally located tumors in the CRT/RT group versus only 1 of 15 patients (7%) in the control group demonstrated MPI defect (p= 0.04). The defects in the CRT/RT group were in the anterior and septal segments while the defects were in different segments in the controls. The median interval between end of RT and MPI was 12.3 months. The affected segments in the CRT/RT group received a mean radiation dose of 39.6 versus 11.4 Gy (p = 0.003) to the normal segments.
  
  
  CONCLUSIONS
  CRT/RT to centrally located lung tumors tends to cause anterior/septal MPI defects. Abnormal MPI segments in the CRT/RT group have received significantly higher radiation than normal segments.
authors.affiliation: Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. isis.w.gayed@uth.tmc.edu
authors.forename: Isis W
authors.initials: IW
authors.lastname: Gayed
authors.forename: H Helen
authors.initials: HH
authors.lastname: Liu
authors.forename: Xiong
authors.initials: X
authors.lastname: Wei
authors.forename: Zhongxing
authors.initials: Z
authors.lastname: Liao
authors.forename: Syed Wamique
authors.initials: SW
authors.lastname: Yusuf
authors.forename: Joe Y
authors.initials: JY
authors.lastname: Chang
authors.forename: Roland
authors.initials: R
authors.lastname: Bassett
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Komaki
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D003326:Coronary Circulation / Q000528:radiation effects*; D005260:Female; D006343:Heart Septal Defects / Q000000981:diagnostic imaging / Q000209:etiology*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D017202:Myocardial Ischemia / Q000000981:diagnostic imaging / Q000209:etiology*; D055414:Myocardial Perfusion Imaging; D011379:Prognosis; D011446:Prospective Studies; D011832:Radiation Injuries / Q000000981:diagnostic imaging / Q000209:etiology*; D050397:Radiotherapy, Intensity-Modulated; D012307:Risk Factors; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome